Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375791 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
A Phase 2 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00375791 is a Phase 2 study that has completed, run by AEterna Zentaris. The registered enrollment target is 67 participants.
The verdict
NCT00375791, a Phase 2 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
Interventions
- DRUG dexamethasone
- DRUG perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00375791
The ClinicalTrials.gov registry entry for NCT00375791 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AEterna Zentaris, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00375791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00375791 about?
NCT00375791 is a clinical study titled "Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma". This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
What is the current status of trial NCT00375791?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2005-12. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00375791?
The interventions under investigation include: dexamethasone (DRUG), perifosine (DRUG).
Who is sponsoring clinical trial NCT00375791?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.